Indanes as NRF2 activators

1. A compound of Formula (II):

wherein:

B is benzotriazolyl, phenyl, triazolopyridinyl, —O—(CH 2 )-triazolyl, or —(CH 2 ) 2 -triazolyl wherein each of benzotriazolyl, phenyl, triazolopyridinyl, —O—(CH 2 )-triazolyl, or —(CH 2 ) 2 -triazolyl is unsubstituted or substituted by 1, 2, or 3 substituents independently selected from —C 1-3 alkyl, —O—C 1-3 alkyl,

—CN, —(CH 2 ) 2 —O—(CH 2 ) 2 —OR 3 and halo;

D is —C(O)OH, —C(O)NR 3 R 4 , —C(O)NHSO 2 CH 3 , —SO 2 NHC(O)CH 3 , —S-(trifluoromethyl)-4H-1,2,4-triazol-2-yl, —NR 3 —C(O)—R 4 , —NR 3 —C(O)—NR 3 R 4 ; —NR 3 —C(O)—O—R 4 or tetrazolyl;

R 1 is independently hydrogen, —C 1-3 alkyl, F, —C 3-6 spirocycloalkyl, oxetane, or the two R 1 groups together with the carbon to which they are attached form a cyclopropyl group;

R 2 is hydrogen, methyl, —CF 3 , or halo;

R 3 is hydrogen or —C 1-3 alkyl;

R 4 is hydrogen, —C 1-5 alkyl, —C 3-7 cycloalkyl, —C 4-8 heterocycloalkyl, —C 1-5 alkoxy, —C 1-3 alkyl-O—C 1-3 alkyl, —C 1-3 alkyl-NH—C 1-3 alkyl, —C 1-3 alkyl-SO 2 C 1-3 alkyl, —C 1-3 alkyl-C 4-8 heterocycloalkyl, —C 1-3 alkyl-C(O)NR 4 R 5 , aryl or heteroaryl, wherein each of —C 1-5 alkyl, —C 3-7 cycloalkyl, —C 4-7 heterocycloalkyl, —C 1-5 alkoxy, —C 1-3 alkyl-O—C 1-3 alkyl, —C 1-3 alkyl-NH—C 1-3 alkyl, —C 1-3 alkyl-C(O)NR 4 R 5 , aryl or heteroaryl is unsubstituted or substituted by one or two substituents selected from —OH, —CO 2 H, —C(O)NR 4 R 5 , —C(O)OR 3 , —N—C(O)—C 1-3 alkyl, F, —CN, —CH—F 2 , —CF 3 , —(CH 2 ) n —O—(CH 2 ) m —CH 3 , —C 3-7 cycloalkyl and a 5-6-membered heteroaryl ring containing 1, 2 or 3 heteroatoms selected from O, N and S;

or R 3 and R 4 together with the nitrogen atom to which they are attached form a 5-8-membered heterocyclic ring, an 8-11-membered bicyclic heterocyclic ring or a 9-10-membered bridged bicyclic heterocyclic ring, wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring optionally includes one —C(O) or one —S(O) 2 , and wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring optionally contains one, two or three oxygen ring atoms, one, two or three sulfur ring atoms or one, two or three nitrogen ring atoms, and wherein each 5-8-membered ring, 8-11-membered bicyclic ring, or 9-10-membered bridged bicyclic ring is unsubstituted or substituted by one, two or three substituents independently selected from —C 1-5 alkyl, —C 3-7 cycloalkyl, —C 4-7 heterocycloalkyl, —(CH 2 )phenyl, halogen, —NR 3 R 5 , —CHF 2 , —CF 3 , and —(CH 2 ) n —O—(CH 2 ) m —CH 3 ;

A is tetrahydrobenzoxazepinyl, tetrahydro-pyrido-oxazepinyl, piperidinyl, tetrahydrobenzazepinyl, phenyl, tetrahydropyrrolopyrazinyl, imidazopyridinyl, tetrahydrobenzodiazepinyl, piperidopyrimidinyl, dioxidotetrahydrothiophenyl, tetrahydroimidazodiazepinyl, oxazepane or morpholinyl;

wherein each of tetrahydrobenzoxazepinyl, tetrahydro-pyrido-oxazepinyl, piperidinyl, tetrahydrobenzazepinyl, tetrahydropyrrolopyrazinyl, imidazopyridinyl, tetrahydrobenzodiazepinyl, piperidopyrimidinyl, dioxidotetrahydrothiophenyl, tetrahydroimidazodiazepinyl, oxazepane or morpholinyl is unsubstituted or substituted by 1, 2, or 3 substituents independently selected from —C 1-3 alkyl, —C 3-6 spirocycloalkyl, halo, —CN, —O—C 1-3 alkyl, —CH 2 —O—CH 3 , and —OH;

and wherein the oxazepane is further unsubstituted or substituted by 1 or 2 substituents independently selected from —C 1-3 alkyl and —C 3-7 cycloalkyl;

and wherein the morpholinyl is further unsubstituted or substituted by phenyl which phenyl is unsubstituted or substituted by a substituent independently selected from —C 1-3 alkyl and —O—C 1-3 alkyl;

or A is

Y is independently selected from N or CH;

E is independently S, O, N;

G is independently C, N;

Z is O, CH 2 , NR 5 , S, S(O) or S(O) 2 ;

R 5 is independently selected from hydrogen or —C 1-4 alkyl;

R 6 is hydrogen, —C 1-5 alkyl or —(CH 2 ) m —C 3-5 cycloalkyl;

R 7 is hydrogen or —C 1-4 alkyl;

or R 6 and R 7 , together with the carbon to which they are attached form a C 3 -C 5 -membered cycloalkyl ring;

and, wherein when A is

it is unsubstituted or substituted with one, two or three substituents independently selected from halo, —CF 3 , —C 1-4 alkyl, —CN, —OMe, —C(O)NH 2 , —OCF 3 and —C 1-4 alkylNR 7 R 8 ;

R 8 is —C 1-3 alkyl, aryl, heteroaryl, —C(O)C 1-3 alkyl, —SO 2 C 1-3 alkyl, —C(O)aryl, —C(O)heteroaryl, —SO 2 aryl, —SO 2 heteroaryl, —C 3-7 cycloalkyl, —C 1-3 alkylC 3-7 cycloalkyl, —C 1-3 alkylC 3-7 heterocycloalkyl,

—C 1-3 alkyl-heteroaryl or —C 1-3 alkyl-aryl, wherein each of —C 1-3 alkyl, aryl, heteroaryl, —C(O)C 1-3 alkyl, —SO 2 C 1-3 alkyl, —C(O)aryl, —C(O)heteroaryl, —SO 2 aryl, —SO 2 heteroaryl, —C 3-7 cycloalkyl, —C 1-3 alkylC 3-7 cycloalkyl, —C 1-3 alkylC 3-7 heterocycloalkyl, —C 1-3 alkyl-heteroaryl or —C 1-3 alkyl-aryl is unsubstituted or substituted by 1, 2 or 3 substituents independently selected from halo, —CN, —CF 3 , —OCF 3 ,

—OCH 3 , —C 1-3 alkyl, —OC 1-3 alkyl, —OC 3-7 cycloalkyl, —OC 3-7 hetercycloalkyl, —O-aryl and —O-heteroaryl;

R 9 is hydrogen, —C 1-5 alkyl or —(CH 2 ) m —C 3-5 cycloalkyl;

R 10 is H, SO 2 R 6 , C(O)R 6 ;

m is 0, 1 or 2; and

n is 1 or 2; or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 and a pharmaceutically acceptable excipient.

3. A method of treating respiratory and non-respiratory disorders, including COPD, asthma, ALI, ARDS, fibrosis, chronic asthma and acute asthma, lung disease secondary to environmental exposures, acute lung infection, chronic lung infection, α1 antitrypsin disease, cystic fibrosis, autoimmune diseases, diabetic nephropathy, chronic kidney disease, sepsis-induced acute kidney injury, acute kidney injury (AKI), kidney disease or malfunction seen during kidney transplantation, Pulmonary Arterial Hypertension, atherosclerosis, hypertension, heart failure, acute coronary syndrome, myocardial infarction, myocardial repair, cardiac remodelling, cardiac arrhythmias, Parkinson's disease (PD), Alzheimer's disease (AD), Friedreich's Ataxia (FA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Huntington's disease (HD), spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Creutzfeldt-Jakob Disease, fatal familial insomnia, Gerstmann-Sträussler-Scheinker syndrome, and related prion diseases, progressive supranuclear palsy, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, retinitis pigmentosa, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, inflammatory bowel disease, colon cancer, neovascular (dry) AMD and neovascular (wet) AMD, eye injury, Fuchs Endothelial Corneal Dystrophy (FECD), uveitis or other inflammatory eye conditions, Non-alcoholic Steatohepatitis (NASH), toxin-induced liver disease (e.g., acetaminophen-induced hepatic disease), viral hepatitis, cirrhosis, psoriasis, dermatitis/topical effects of radiation, immunosuppression due to radiation exposure, Preeclampsia, and high altitude sickness which comprises administering to a human in need thereof, a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, according to claim 1 .

4. The method according to claim 3 wherein the compound, or a pharmaceutically acceptable salt thereof, is administered orally.

5. The method according to claim 3 wherein the compound, or a pharmaceutically acceptable salt thereof, is administered intravenously.

6. The method according to claim 3 wherein the compound, or a pharmaceutically acceptable salt thereof, is administered by inhalation.

7. The method according to claim 3 wherein the disease is COPD.

8. The method according to claim 3 wherein the disease is heart failure.